MRNA Aug 2024 140.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

1.5900

+0.0900

(+6.00%)

As of 10:28AM EDT. Market open.

Loading interactive chart...

Zacks
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.
Barrons.com
GSK Will Pay Up to $1.5 Billion for CureVac’s mRNA Vaccines
CureVac is also eligible for future royalties. CureVac shares jumped 12% in early trading Wednesday, while GSK’s American depositary receipt slipped 0.2%. Shares of Moderna a leading mRNA vaccine manufacturer, were up 0.9%.
Zacks
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.